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Introduction: Atrial fibrillation (AF) is often associated with several comorbidities. The 
Charlson Comorbidity Index (CCI) is an established tool for evaluating the burden of 
comorbidity, but limited data are available relating AF and CCI. We analyzed the 
relationship between AF and CCI in a population-based cohort study over a long-term 
follow-up period, in relation to oral anticoagulant (OAC) drug prescriptions and major 
adverse events. 
Methods: We used data from the administrative health databases for the whole Lombardy 
region of Italy (>10 million inhabitants). All patients admitted in 2002 and diagnosed with 
AF were considered for analysis and subjects were followed up for 12 years. AF diagnosis 
and CCI were established according to ICD-9 codes retrieved from hospital admissions. 
Results: In 2002, 24040 patients were admitted with a diagnosis of AF, and CCI was 
significantly higher in AF patients compared to non-AF subjects (1.8±2.1 vs. 0.2±0.9, 
p<0.001). Over 12-years follow-up, AF was associated with an independent increased risk 
of higher CCI, compared to non-AF subjects (beta coefficient: 1.69, 95% confidence 
interval [CI]: 1.67-1.70). Adjusted logistic regression analysis found that in AF patients, 
CCI was inversely associated with OAC prescription at baseline (odds ratio [OR]: 0.91, 
95% confidence interval [CI]: 0.89-0.92 per point), as well as at the end of follow-up (OR: 
0.98, 95% CI: 0.98-0.99). 
Over the 12-years follow-up, AF patients with high CCI (≥4) had a higher cumulative 
incidence for stroke, major bleeding and all-cause death (all p<0.001), compared to those 
with low CCI (0-3).  Adjusted Cox regression analysis found that CCI, considered as a 
time-dependent continuous variable, was independently associated with an increased risk 
for stroke (hazard ratio [HR]: 1.04, 95% CI: 1.02-1.06 per point), major bleeding (HR: 1.03, 
95% CI: 1.01-1.06) and all-cause death (HR: 1.10, 95% CI: 1.09-1.11). 
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Conclusions: In hospitalized patients, AF is associated with an independent increase in 
CCI, that was inversely associated with OAC prescriptions during follow-up. CCI was 
independently associated with an increased risk of stroke, major bleeding and all-cause 
death. 
 




Atrial fibrillation (AF) has an increasing incidence, prevalence and impact on healthcare 
systems globally1.  The AF worldwide epidemic is mainly owed to the increasing 
population ageing, affecting more likely older patients3. Compared to the past, AF patients 
are often older and more affected with concomitant cardiovascular (CV) and non-
cardiovascular comorbidities, that affect significantly patients’ clinical course, leading to an 
increased risk of CV death and all-cause death4. 
 
The concept of comorbidity, or more precisely multimorbidity (defined as the concomitant 
presence of two or more chronic conditions) has gained much medical attention in the last 
decades5.  As with AF, the prevalence of multimorbidity increases with increasing age and 
is associated with a high risk of mortality, reduced functional status, increased healthcare 
expenditure and use of resources6. As part of the biological, sociological and clinical 
complexity associated with healthcare7, multimorbidity demands solid integrated care and 
a holistic approach to the patient in order to proper manage the associated risks6. 
Moreover, comorbidity/multimorbidity is very common in patients with CV disease8. 
 
The Charlson Comorbidity Index (CCI) has been validated as a reliable tool to evaluate the 
burden of comorbidity/multimorbidity in the general population and is significantly 
associated with an increased risk of all-cause death during long-term follow-up9. 
Furthermore, CCI has been extensively validated in patients with CV disease10. 
Nevertheless, despite AF being associated with several comorbidities1, scarce data exist 
about the overall burden of comorbidities and the relationship of CCI with AF. 
 
The aim of this paper is to evaluate the relationship between AF, burden of comorbidity (as 
defined by CCI), the prescription of oral anticoagulant (OAC) drugs and long-term 
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Data Source and Study Population 
This study used linkable administrative health databases of the Lombardy Region which 
include a population registry with the demographic data of all residents and detailed 
information on drug prescriptions and hospital admissions. To date, with a population of 
more than 10 million inhabitants, Lombardy is the largest Italian region, comprising highly 
populated urban areas, as well as industrial and rural ones. The Italian healthcare system 
is based on a public National Health System, which provides assistance to anyone on 
national territory, irrespective of any pre-existing condition. A personal identification 
number is given to each subject and kept in the National Civil Registration System.  
 
All databases are linked anonymously using unique encrypted patient codes, in 
accordance with Italian privacy regulations. Approval from an ethics committee is not 
required to analyse encrypted administrative data. Data were available for fifteen 
consecutive years, from 2000 to 2014. For any hospital admission, all discharge diagnoses 
have been coded according to International Classification of Disease 9th revision [ICD-9]. 
Moreover, the hospital discharge database records the date of hospital admission, date of 
discharge or death and procedures performed during admission. The drug prescription 
database contains the drug name and its Anatomical Therapeutic Chemical (ATC) 
classification code, quantity and dispensation date. All data about subjects 40 years and 
older were included in this analysis.  
 
 6 
Data from 2000 to 2001 were used to build the clinical history of patients and to calculate 
CCI. Year 2002 was used as index year to evaluate AF diagnosis. All discharge diagnoses 
were searched for codes 427.31 and 427.32, and all subjects with these codes irrespective 
of diagnosis position, were assigned to the group of patients with prevalent AF. All other 
subjects entered the control group of non-AF patients. 
 
Definition of Concomitant Comorbidities and CCI Calculation 
According to the diagnoses reported at discharge and coded as per ICD-9, all patients 
were evaluated for concomitant presence of comorbidities (see Supplementary Materials, 
Table S1). Hypertension was identified on the basis of prescription of at least an 
antihypertensive drug in the six months after entering the study cohort (see Table S1 for 
ATC codes). Accordingly, the CHA2DS2-VASc score was computed according to the 
original definitions11. 
 
In its original definition, CCI comprised 19 diagnosis to which different weights have been 
assigned and summed to obtain the final calculation of CCI9 (Table S2). For this study, the 
CCI was calculated according to a validated method applied to the administrative 
databases12. All AF patients were grouped according to CCI as patients with low 
comorbidity (CCI 0-3) and high comorbidity (CCI ≥4).  
 
In order to analyze the relationship between AF and CCI, we analyzed differences at 
baseline between AF and non-AF patients. Then, we analyzed the relationship between 
AF and CCI throughout the follow-up observation, to establish if a significant association 
exists between AF and increasing comorbidity burden according to CCI. 
 
Oral Anticoagulant Drugs 
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In the purpose of the study we evaluated OAC prescription at baseline and at the end of 
observation according to CCI. At the beginning of observation, only vitamin K antagonists 
(VKAs) were available, while at the end of observation the non-vitamin K antagonist oral 
anticoagulants (NOACs) were available for prescription. OAC drugs prescription were 
recorded as follows: VKA (warfarin: B01AA03, acenocumarol: B01AA07); NOACs 
(dabigatran: B01AE07, rivaroxaban: B01AF01, apixaban: B01AF02, edoxaban: B01AF03), 
antiplatelet drugs (B01AC). 
 
Study Outcomes  
Outcomes of interest for the present study were: stroke, major bleeding and all-cause 
death (see Supplementary Materials, Table S1 for ICD-9 codes). Follow-up observation 
started when the patient entered the study cohort and proceeded until one of the outcomes 
occurred or when the follow-up was censored. Reasons to be censored included 




Continuous variables, expressed as mean and standard deviation, were compared across 
the groups using Student’s t-test. Categorical variables, expressed as counts and 
percentages, were compared using Chi-square test.  
 
To analyse the relationship between AF and CCI over follow-up, we performed a mixed 
linear effect logistic model adjusted for years of observation, age, sex and an interaction 
term between AF and follow-up years. A supplementary age-stratified (<65 years, 65-74 
years, ≥75 years) analysis was also performed. 
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To evaluate the impact of CCI in OAC prescription for AF patients, we performed a logistic 
regression model, adjusted for age and sex, for OAC prescription at baseline and at the 
end of follow-up. CCI was considered as a continuous variable and as classes (high vs. 
low comorbidity). At the end of follow-up, we separately prescriptions of VKA and NOACs. 
 
Differences in survival between AF patients with low and high comorbidity were analyzed 
with Log-Rank test and Kaplan-Meier curves were drafted accordingly. A Cox regression 
analysis to evaluate the impact of CCI, considered as a continuous time-dependent 
variable, in determining study outcomes was performed. Two Cox regression models were 
performed, as follows: i) adjusted for age and sex; ii) adjusted for age, sex and OAC 
prescription. A two-sided value of p ≤ 0.05 was considered statistically significant. 
Analyses were done with Stata 13.0 (Stata Corp LP, College Station, TX, USA), and SAS 





In 2002, a total of 24,040 AF patients were retrieved, as well as 240,400 non-AF patients. 
At baseline (Table 1), AF patients had a significantly higher mean (±SD) CCI than non-AF 
subjects (1.8±2.1 vs. 0.2±0.9, p<0.001). Patients with AF were significantly older and more 
likely male, and more likely affected by comorbidities compared to non-AF subjects. 
Accordingly, AF patients had a significantly higher mean (±SD) CHA₂DS₂-VASc score 
compared to non-AF subjects (3.3±1.4 vs. 1.4±1.2, p<0.001). 
 
Among the overall AF patient cohort, 4295 (17.9%) patients had high comorbidity (CCI ≥4), 
while 19,745 (82.1%) had low comorbidity (CCI 0-3) (Table 1). Mean (±SD) CCI for the 
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high comorbidity group was 5.5±1.8, while for the low comorbidity group, 1.1±1.1 
(p<0.001). Patients with high comorbidity were older and more likely male than those with 
low comorbidity (both p<0.001). In patients with high comorbidity all conditions considered 
were more prevalent, except for hypertension which was more prevalent in the low 
comorbidity group (p<0.001). Patients with high comorbidity had a higher thromboembolic 
risk than the low comorbidity group (CHA₂DS₂-VASc score mean [±SD] 4.1±1.5 vs. 
3.2±1.3, accordingly; p<0.001). At baseline, patients with high comorbidity group were 
significantly less prescribed with OAC than those with low comorbidity (30.0% vs. 42.3%, 
p<0.001). 
 
Trends in CCI and Relationship with AF 
A mixed linear effect logistic model was compiled to analyze the relationship between AF 
and CCI. Overall, mean CCI progressively increased over time both in non-AF and AF 
patients, being increasingly and steadily higher in AF patients compared to non-AF ones 
(p<0.001) [Figure 1]. After adjustment for years of observation, age, sex and an interaction 
term between AF and years of observation, AF was significantly associated with an 
increasingly higher CCI (coefficient: 1.69, 95% confidence interval [CI]: 1.67-1.70), F= 
99943.8, p<0.001). Subgroup analysis for age classes, showed that this relationship was 
consistently significant for patients <65 years, 65-74 years and ≥75 years (all p<0.001) 
[Figure S1-S3]. 
 
CCI and OAC Prescription 
After multivariable adjustment (Table 2), CCI as a continuous variable was inversely 
associated with OAC prescription (odds ratio [OR]: 0.91, 95% CI: 0.89-0.92). The high 
comorbidity category (CCI ≥4) was significantly inversely associated with OAC prescription 
(OR: 0.65, 95% CI: 0.60-0.70).  
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At the end of follow-up, even though CCI as a continuous variable was inversely 
associated with OAC prescription (OR: 0.98, 95% CI: 0.98-0.99), the high comorbidity 
category was not significantly associated (OR: 0.98, 95% CI: 0.93-1.04). Examining 
separately VKA and NOACs prescription (Table 2), while there was no difference in VKA 
prescription, both continuous and categorical CCI were significantly inversely associated 
with prescription of NOACs (both p<0.001). 
 
Survival and Regression Analysis 
At follow-up, all the outcomes considered were more likely in the high comorbidity group 
(Table 3). Kaplan-Meier analysis shows that risk for stroke, major bleeding and all-cause 
death was consistently higher in high comorbidity group compared to the low comorbidity 
group [Figure 2]. 
 
Cox regression analysis, using CCI as a continuous time-dependent variable to take 
account of the temporal increase and adjusted for age, sex and use of OAC, CCI was 
significantly directly associated with an increased risk for stroke (hazard ratio [HR]: 1.04, 
95% CI: 1.02-1.06 per increasing point), major bleeding (HR: 1.03, 95% CI: 1.01-1.06 per 






Our study showed that AF patients are exposed to a higher burden of overall comorbidity 
than compared to non-AF ones, showing for the first time that exist a direct relationship 
between AF and increasing comorbidity burden over long-term follow-up, irrespective of 
age. Second, an increased burden of comorbidity is inversely associated with OAC 
prescription, which could significantly affect AF patients’ clinical history. Third, an 
increased burden of comorbidity in AF patients is directly and independently associated 
with an increased risk for stroke, major bleeding and all-cause death. 
 
The independent relationship between various single diseases and AF has been largely 
demonstrated. Indeed, several conditions contribute independently to incident AF 
occurrence and it has been suggested how tight control of concomitant risk factors and 
comorbidities could significantly reduce the burden of AF13,14. Furthermore, several 
diseases are independently prevalent in AF patients15,16. Our paper firstly establishes a 
direct link between the presence of AF and the development of a progressively higher 
burden of comorbidity (or better rather, multimorbidity). The evidence presented allows us 
to speculate about the role of AF as a proxy of a worst clinical status. 
 
Our data are strengthened by the use of a solid and validated tool to evaluate 
comorbidity/multimorbidity, the CCI. Thus far, data about CCI in the contest of AF are 
scarce17. In a Belgian study derived from a primary care registry, a modified version of the 
CCI was found significantly higher in AF elderly (≥60 years) patients than in non-AF ones, 
also being significantly associated with AF diagnosis17. The data presented in this study 
extend this previous evidence, confirming how the burden of comorbidity is significant in 
AF patients, irrespective of age and of what may be single medical conditions. In 
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particular, we  show how a significant proportion of patients (~20%) had a high level of 
comorbidity. A recent study derived from the UK Biobank, in a cohort of patients with self-
reported AF which examined the presence of multimorbidity as the additive presence of 
various conditions, only 19.6% of patients reported no comorbidities and 11.1% of patients 
reported 4 or more comorbidities18. 
 
Our results presented show that increased comorbidity in AF patients is significantly 
inversely associated with OAC prescription. This is a concerning trend, considering the 
associated increased thromboembolic risk. In the study by Vanbeselaere and colleagues, 
there was a possible inverse relationship between increasing CCI and reduced OAC 
prescription17. Our study extends the previous knowledge, showing how this inverse 
relationship is consistent in general population and over a long-term observation period. 
Moreover, we showed that if physicians appear to be more confident in prescribing VKA, 
the prescription of NOACs is significantly reduced in patients with increased comorbidity. 
Our results substantiate previous observations that seem to suggest that AF patients 
prescribed with NOACs are relatively healthier and have less prevalent comorbidities15,19. 
 
In the recent years, the increased risk of CV-related and all-cause death in AF cohorts has 
shifted the main focus of prevention of adverse events from stroke to mortality20–25. Our 
data show that the increased and increasing comorbidity burden is strongly associated 
with an increased risk of all the adverse events, stroke, major bleeding and all-cause 
death. The Framingham Heart Study previously showed how AF patients with 
comorbidities have a consistently increased risk for cardiovascular events and all-cause 
death compared to those without26. An analysis from the “Outcomes Registry for Better 
Informed Treatment of Atrial Fibrillation” (ORBIT-AF) study showed that when clustering 
AF patients according to the more frequent clinical characteristics, those patients in the 
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‘low-comorbidity’ cluster had the lowest risk major cardiovascular and neurological adverse 
events than all the other identified clusters, variously affected by risk factors and other 
comorbidities16. 
 
Our paper also extends previous knowledge about the usefulness of CCI in AF patients. 
Thus far CCI have been already validated in patients with acute coronary syndrome27 and 
stroke28 and other cardiovascular conditions10. Our study represents the first large 
evaluation of CCI in a population-based AF patients’ cohort. 
 
In the recent years there has been an increasing need of new approaches to manage AF 
patients, considering them in a more comprehensive, integrated and holistic way. A 
systematic review and meta-analysis by Gallagher and colleagues showed how an 
integrated care approach can significantly reduce hospitalization and mortality in AF 
patients29. Various expert opinions and international consensus statements have proposed 
new integrated models to proper manage AF patients, with the ultimate objective to reduce 
the risk of adverse events30,31. The ABC pathway has recently been proposed as a 
possible model to integrate the various main aspects related to AF patients’ management, 
in order to streamline and facilitate integrated care and holistic evaluation of these 
patients32. Our data support this new approach and advocate the need for structured 
integrated and holistic management of AF patients. 
 
Limitations 
The main limitation of this study is related to the use of ICD-9 codes, that even if largely 
validated in clinical research, cannot completely exclude some risk of bias related to 
inaccuracies and coding mistakes; furthermore, this tool does not allow us to consider and 
evaluate some relevant factors for adverse outcomes in AF patients. Second, since all 
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data are retrieved from hospital admissions, our study results need to be cautiously 
generalized to the overall AF population. Lastly, we used an adapted model of CCI 
conceived for the use in health administrative databases, which was also evaluated 
retrospectively and not at the baseline observation. Notwithstanding these limitations, we 
provided the first evidence of a direct relationship between AF and increasing burden of 
comorbidity and the largest validation of CCI as a reliable tool for evaluation of comorbidity 
in AF patients and its association with major adverse events. 
 
CONCLUSION 
In hospitalized patients, AF is associated with an independent increase in CCI, that was 
inversely associated with OAC prescriptions during follow-up. CCI was independently 
associated with an increased risk of stroke, major bleeding and all-cause death. New 
models of care able to consider the burden of comorbidities in AF patients and offer 
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Figure 1: Charlson Comorbidity Index Trends according to Atrial Fibrillation 
Diagnosis 
Legend: Whiskers stand for standard deviation of mean; AF= Atrial Fibrillation; CCI= 
Charlson Comorbidity Index. 
 
Figure 2: Kaplan-Meier Curves for Major Adverse Events according to Charlson 
Comorbidity Index Classes 
Legend: CCI= Charlson Comorbidity Index.  
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Age, years mean±SD 59.7±13.2 76.1±9.8 <0.001 75.7±9.9 77.8±8.8 <0.001 
Age classes, n (%) 
 
<0.001   <0.001 
<65 years 155310 (64.6) 2964 (12.3) 
 
2651 (13.4) 313 (7.3)  
65-74 years 47525 (19.8) 6702 (27.9) 
 
5611 (28.4) 1091 (25.4)  
≥75 years 37565 (15.6) 14374 (59.8) 
 
11483 (58.2) 2891 (67.3)  
Male, n (%) 11096 (46.2) 12079 (50.2) <0.001 9841 (49.8) 2238 (52.1) <0.001 
Charlson Comorbidity Index, (mean±SD) 0.2±0.9 1.8±2.1 <0.001 1.1±1.1 5.5±1.8 <0.001 
Hypertension, n (%) 79801 (33.2) 18605 (77.4) <0.001 15452 (78.3) 3153 (73.4) <0.001 
Diabetes Mellitus, n (%) 4316 (1.8) 3555 (14.8) <0.001 1763 (8.9) 1792 (41.7) <0.001 
Myocardial Infarction, n (%) 1723 (0.7) 1400 (5.8) <0.001 869 (4.4) 531 (12.4) <0.001 
Congestive Heart Failure, n (%) 2919 (1.2) 7249 (30.1) <0.001 4882 (24.7) 2367 (55.1) <0.001 
Cerebrovascular Disease, n (%) 3216 (1.3) 3605 (15.0) <0.001 1625 (8.2) 1980 (46.1) <0.001 
Hemiplegia, n (%) 2282 (0.9) 2830 (11.8) <0.001 1027 (5.2) 1803 (42.0) <0.001 
Dementia, n (%) 489 (0.2) 400 (1.7) <0.001 197 (1.0) 203 (4.7) <0.001 
COPD, n (%) 3125 (1.3) 4017 (16.7) <0.001 2523 (12.8) 1494 (34.8) <0.001 
Connective Tissue Disease, n (%) 560 (0.2) 303 (1.3) <0.001 228 (1.1) 75 (1.7) 0.002 
Ulcer, n (%) 620 (0.3) 440 (1.8) <0.001 287 (1.4) 153 (3.6) <0.001 
Mild Liver Disease, n (%) 1918 (0.8) 1212 (5.0) <0.001 669 (3.4) 543 (12.6) <0.001 
Moderate/Severe Liver disease, n (%) 769 (0.3) 334 (1.4) <0.001 44 (0.2) 290 (6.7) <0.001 
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Legend: AF= Atrial Fibrillation; CCI= Charlson Comorbidity Index; COPD= Chronic Obstructive Pulmonary Disease; SD= Standard 
Deviation. 
  
Renal Disease, n (%) 1244 (0.5) 2087 (8.7) <0.001 788 (4.0) 1299 (30.24) <0.001 
Metastatic Tumor, n (%) 1162 (0.5) 503 (2.1) <0.001 0 (0.0) 503 (11.7) <0.001 
Leukemia, n (%) 117 (0.1) 86 (0.4) <0.001 49 (0.2) 37 (0.9) <0.001 
Lymphoma, n (%) 305 (0.1) 190 (0.8) <0.001 90 (0.5) 100 (2.3) <0.001 
Any Tumor, n (%) 4423 (1.8) 2189 (9.1) <0.001 1124 (5.7) 1065 (24.8) <0.001 
CHA₂DS₂-VASc, (mean±SD) 1.4±1.2 3.3±1.4 <0.001 3.2±1.3 4.1±1.5 <0.001 
Oral Anticoagulant Drugs, n (%) 4141 (1.7) 9646 (40.1) <0.001 8358 (42.3) 4295 (30.0) <0.001 
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Table 2: Logistic Regression Analysis for Oral Anticoagulant Drugs Prescription according to Charlson Comorbidity Index 
 OAC Prescription at Baseline OAC Prescription at End of Follow-Up 
 OR 95% CI p OR 95% CI p 
CCI (as continuous variable) 0.91 0.89-0.92 <0.001 0.98 0.98-0.99 <0.031 
CCI ≥4 (vs. CCI 0-3) 0.65 0.60-0.70 <0.001 0.98 0.93-1.04 0.494 
 VKA Prescription at End of Follow-Up NOACs Prescription at End of Follow-Up 
 OR 95% CI p OR 95% CI p 
CCI (as continuous variable) 0.99 0.98-1.00 0.220 0.86 0.81-0.90 <0.001 
CCI ≥4 (vs. CCI 0-3) 1.00 0.95-1.06 0.944 0.48 0.37-0.63 <0.001 
Legend: CCI= Charlson Comorbidity Index; NOACs= Non-Vitamin K Antagonists Oral Anticoagulants; OAC= Oral Anticoagulants; 
VKA= Vitamin K Antagonist. 
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Table 3: Major Adverse Events according to Charlson Comorbidity Index Classes  





 N Cumulative Incidence* N Cumulative Incidence*  
Stroke 1826 17.4 412 26.0 <0.001 
Major Bleeding 1120 12.0 197 15.7 <0.001 
All-Cause Death 13831 76.0 3650 95.0 <0.001 
Legend: *per 100 patients; CCI= Charlson Comorbidity Index. 
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Table 4: Cox Regression Analysis for Major Adverse Events 
 Charlson Comorbidity Index  
(as continuous time-dependent variable) 
 Model 1* Model 2† 
 HR 95% CI p HR 95% CI p 
Stroke 1.04 1.03-1.06 <0.001 1.04 1.02-1.06 <0.001 
Major Bleeding 1.02 0.99-1.04 0.146 1.03 1.01-1.06 <0.001 
All-Cause Death 1.10 1.09-1.11 <0.001 1.10 1.09-1.11 <0.001 
Legend: *adjusted for sex and age; †adjusted for sex, age and use of OAC; CI= Confidence Interval; HR= Hazard Ratio; OAC= Oral 
Anticoagulant. 
